Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Trial Profile

A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Niraparib (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jan 2019 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.
    • 03 Jan 2019 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.
    • 03 Jan 2019 Planned initiation date changed from 1 Nov 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top